文献速递急性肾损伤

同种异体间充质干细胞治疗心脏术后急性肾损伤

Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery.
PubMed 文献 · J Am Soc Nephrol · 2017-10-16

这项2期随机双盲安慰剂对照试验在北美27个中心纳入156例心脏术后早期AKI成人患者,比较主动脉内注射同种异体人间充质干细胞(AC607)与安慰剂的效果。主要结局肾功能恢复时间两组无显著差异(15天 vs 12天,HR 0.81,95%CI 0.53-1.24,P=0.32),30天全因死亡率和透析率亦无显著差异。

要点

  • 同种异体MSCs未缩短心脏术后AKI的肾功能恢复时间。
  • 30天全因死亡率和透析率组间无显著差异。
  • 结果与临床前研究相反,提示需重新评估MSCs在此场景的作用。

核心结论

  • 在心脏术后AKI患者中,给予同种异体MSCs未减少肾功能恢复时间。

研究设计与样本

  • 2期随机双盲安慰剂对照试验,北美27个中心,156例心脏术后早期AKI成人患者随机接受AC607(n=67)或安慰剂(n=68)。

主要发现

  • 肾功能恢复中位时间AC607组15天 vs 安慰剂组12天(25-75百分位10-29 vs 6-21),HR 0.81(95%CI 0.53-1.24,P=0.32)。
  • 30天全因死亡率AC607组16.7% vs 安慰剂组11.8%,透析率10.6% vs 7.4%,均无显著差异。
  • 随访期间AC607组12例、安慰剂组6例死亡,其他不良事件率组间无差异。

临床怎么用

  • 不推荐将同种异体MSCs用于心脏术后AKI以加速肾功能恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AKI after cardiac surgery remains strongly associated with mortality and lacks effective treatment or prevention. Preclinical studies suggest that cell-based interventions may influence functional recovery. We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers across North America to determine the safety and efficacy of allogeneic human mesenchymal stem cells (MSCs) in reducing the time to recovery from AKI after cardiac surgery. We randomized 156 adult subjects undergoing cardiac surgery with evidence of early AKI to receive intra-aortic MSCs (AC607; n=67) or placebo (n=68). The primary outcome was the time to recovery of kidney function defined as return of postintervention creatinine level to baseline. The median time to recovery of kidney function was 15 days with AC607 and 12 days with placebo (25th, 75th percentile range, 10-29 versus 6-21, respectively; hazard ratio, 0.81; 95% confidence interval, 0.53 to 1.24; P=0.32). We did not detect a significant difference between groups in 30-day all-cause mortality (16.7% with AC607; 11.8% with placebo) or dialysis (10.6% with AC607; 7.4% with placebo). At follow-up, 12 patients who received AC607 and six patients who received placebo had died. Rates of other adverse events did not differ between groups. In these patients with AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of kidney function. Our results contrast with those in preclinical studies and provide important information regarding the potential effects of MSCs in this setting.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. J Am Soc Nephrol. 2017. PMID: 29038286. doi:10.1681/ASN.2016101150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。